ライフサイエンスコーパス: CCR5 receptor

1 ignificantly if the target cell co-expresses CCR5 receptor.

2 rated by antagonist binding to the chemokine CCR5 receptor.

3 e binding sites for the 17b antibody and the CCR5 receptor.

4 l blood mononuclear cells (PBMC) lacking the CCR5 receptor.

5 the disease progression and upregulation of CCR5 receptor.

6 e was selected as a targeting ligand for the CCR5 receptor.

7 nes with high levels of both the CD4 and the CCR5 receptors.

8 receptors, but not the CXCR4, CCR2, CCR4, or CCR5 receptors.

9 nds to the lower-energy conformations of the CCR5 receptor and 11 mutants.

10 R5 receptor levels and greater resistance to CCR5 receptor and fusion inhibitors compared to those wi

11 omains, increase both the ability to use the CCR5 receptor and fusion kinetics.

12 The CTL clones expressed the CCR5 receptor and localized among HIV-infected cells exp

13 and RANTES, interfere with HIV-1 binding to CCR5 receptors and decrease the amount of virions enteri

14 erial smooth muscle cells express functional CCR5 receptors and MIP-1beta is an agonist for these cel

15 eptor, but retained the ability to stimulate CCR5 receptors and to inhibit the cytopathic effects of

16 was established before the discovery of the CCR5 receptor, and there have since been multiple report

17 genous RANTES (44AANA47-RANTES) nor the CCR1/CCR5 receptor antagonist, methionylated-RANTES, had an e

18 t LukED-dependent cell killing is blocked by CCR5 receptor antagonists, including the HIV drug maravi

19 We first used a chimeric CCR2/CCR5 receptor approach to obtain insight into the bindin

20 ively use the CXCR4 receptor rather than the CCR5 receptor are less neutralization susceptible, espec

21 ors of the chemokine (C-C motif) receptor 5 (CCR5) receptor are compared for their potency as inhibit

22 ibitors of RANTES activity, Met-RANTES and a CCR5 receptor-blocking antibody.

23 oth conventional antiretroviral regimens and CCR5 receptor-blocking drugs will promote R5 virus over

24 oluble Env proteins to either the CD4 or the CCR5 receptor, but studies with a fusion-arrested Env in

25 study we show that activation of the CD4 or CCR5 receptor by R5 HIVenv causes a caspase 8-dependent

26 In the present study, donor CCR5 density (CCR5 receptors/CD4 lymphocytes) inversely correlated wit

27 n and prevents its attachment to the CD4 and CCR5 receptors, CMPD167, a small molecule that binds to

28 ing site agrees with the recent structure of CCR5 receptor cocrystallized with Maraviroc.

29 ure-activity relationships (SAR) and a human CCR5 receptor docking model using the crystal structure

30 DC) maturation, CC-chemokine production, and CCR5 receptor expression was examined using a soluble tr

31 hich demand consideration when targeting the CCR5 receptor for therapeutic strategies.

32 ing CC chemokine receptor (CCR) 1, CCR3, and CCR5 receptors for RANTES chemokine was increased by Ang

33 cxcl10) chemotactic chemokines and ccr1 and ccr5 receptor genes, evaluated by reverse transcription-

34 sensitive and specific PET/CT imaging of the CCR5 receptor in an apolipoprotein E knock-out (ApoE(-/-

35 have V3 loop protrusions that interfere with CCR5 receptor interactions.

36 ian two-hybrid systems, we observed that the CCR5 receptor is constitutively associated with the zeta

37 eased ability to replicate in cells with low CCR5 receptor levels and greater resistance to CCR5 rece

38 While the inability to utilize the CCR5 receptor maps to a predicted protrusion in the enve

39 CD4(+) T cells almost exclusively by CD4 and CCR5 receptor-mediated direct fusion, without requiring

40 raction of the HIV envelope with the CD4 and CCR5 receptor molecules present on the surface of target

41 tected macaques post challenge show complete CCR5 receptor occupancy and an absence of viral nucleic

42 ding to the virus itself and by blocking the CCR5 receptor on host cells.

43 (HIV) envelope gp120 glycoprotein to CD4 and CCR5 receptors on the plasma membrane initiates the vira

44 ients homozygous for a nonfunctional Delta32 CCR5 receptor rarely exhibit late graft loss.

45 functional "bridge" for the transmission of CCR5 receptor signaling to the cytoskeleton and nucleus,

46 PET receptor blocking studies confirmed the CCR5 receptor-specific uptake.

47 high dose' vaginal transmission model with a CCR5-receptor-using simian-human immunodeficiency virus

48 itic cells (DCs) with HIV-1 involves CD4 and CCR5 receptors, while transmission to T cells is enhance

49 truncated mutant MIP(9) was able to bind the CCR5 receptor with a K(i) of 600 pM but displayed weak a